样式: 排序: IF: - GO 导出 标记为已读
-
Posaconazole versus voriconazole as antifungal prophylaxis for invasive fungal diseases in patients with hematological malignancies J. Oncol. Pharm. Pract. (IF 1.3) Pub Date : 2024-04-24 Reem Almutairy, Mansoor Ahmed Khan, Alaa Shahbar, Mohammed Aseeri, Majed Alshamrani, Hassan Almarhabi, Doaa Naeem
IntroductionThe incidence of invasive fungal diseases (IFDs) has risen in hematologic malignancy patients due to neutropenia. While posaconazole is recommended as the first-line antifungal prophylaxis in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) patients and voriconazole is an alternative, there is currently no direct comparison data available to assess their relative effectiveness
-
Antibody drug conjugates: Design implications for clinicians J. Oncol. Pharm. Pract. (IF 1.3) Pub Date : 2024-04-23 Stephanie Pang, Arianne Duong, Chloe Siu, Amy Indorf
ObjectiveThere are currently 11 antibody-drug conjugates (ADC) that are FDA approved for use in oncologic disease states, with many more in the pipeline. The authors aim to review the pharmacokinetic profiles of the components of ADCs to engage pharmacist practitioners in practical considerations in the care of patients. This article provides an overview on the use of ADCs in the setting of organ dysfunction
-
Evaluation of colitis induced by immune-checkpoint inhibitors therapy in melanoma patients by an overall grading scale J. Oncol. Pharm. Pract. (IF 1.3) Pub Date : 2024-04-23 Trang L. Nguyen, Alice Tew, Laura Kirton, Neil Steven
BackgroundColitis was the third most common immune-related adverse effect in melanoma patients treated with immune-checkpoint inhibitor (ICI). With the limitation of real-world data in the UK population, this study was conducted in a UK hospital where a fresh colitis guidance was introduced to evaluate the overall grading (OG) to assess colitis severity and guide the treatment.AimsThis study aimed
-
Immune-related adverse effects: Recognition and initiation of appropriate treatment in cancer patients on immunotherapy J. Oncol. Pharm. Pract. (IF 1.3) Pub Date : 2024-04-22 Riley Mohr, Anna Howard, Melanie Townsend
PurposeDelayed or improper identification of immune-related adverse events (IRAEs) during cancer treatment can impact time to receive proper treatment. This study describes rates of IRAE recognition and appropriate treatment in adult patients with cancer at a community teaching hospital.MethodsThis single-center, retrospective, cohort study evaluated rates of proper IRAE treatment in conjunction with
-
A comparative review of Aphexda and Mozobil for mobilization prior to stem cell collection J. Oncol. Pharm. Pract. (IF 1.3) Pub Date : 2024-04-17 Lauren Dietz, Jessica Marini, Hamza Hashmi, Mary McGann
High-dose chemotherapy followed by autologous hematopoietic stem cell transplantation is the standard of care for eligible patients with newly diagnosed multiple myeloma leading to prolonged progression free and overall survival. Successful engraftment following hematopoietic stem cell infusion requires adequate stem cell doses. Current mobilization regimens include granulocyte colony-stimulating factor
-
Securing the oral and enteral oncopediatric chemotherapy process in pediatric oncology: Introduction of the ENFit™ standard in a controlled-atmosphere area and implementation of a dispensing service of medications to outpatients circuit with advice on proper use J. Oncol. Pharm. Pract. (IF 1.3) Pub Date : 2024-04-13 Elise Poutrain, Marie Abelé-Naveau, Marion Baltora, Alexandre Villain, Ilyes Sakji, Geoffrey Strobbe, Guillaume Marliot
IntroductionOral chemotherapies pediatrics are manufactured from injectable specialties in a controlled-atmosphere area. Packaged in Luer-Lock syringes, the transition to an ENFit™ connector became crucial to enable administration in surveyed patients. In parallel, a study was carried out to optimize and secure patient care by setting up a retrocession circuit.ObjectiveTo introduce the ENFit™ range
-
Retrospective review of the toxicities and change in dosing patterns for pegaspargase in patients with acute lymphoblastic leukemia/lymphoma and T-cell lymphoma J. Oncol. Pharm. Pract. (IF 1.3) Pub Date : 2024-04-13 Grace Baek, Miryoung Kim, Madison Lee, Shan O’Connor, Lauren Held, Lars van der Laan, Ryan D Cassaday
IntroductionPegaspargase (PEG) is a key component of standard regimens for acute lymphoblastic leukemia/lymphoma (ALL) and extranodal natural killer/T-cell lymphoma (NKTCL). Emerging evidence suggests an opportunity to decrease incidence of PEG-associated toxicities with dose capping, but evidence is limited. This study aims to evaluate whether a significant difference in PEG-associated toxicities
-
Real-world treatment outcomes from nationwide Onco-colon Turkey registry in RAS wild-type patients treated with biologics second-line mCRC J. Oncol. Pharm. Pract. (IF 1.3) Pub Date : 2024-04-13 Mahmut Emre Yildirim, Nuri Karadurmuş, İlker Nihat Ökten, Hacı Mehmet Türk, Zuhat Urakçı, Çağatay Arslan, Sinemis Çelik, Faysal Dane, Mehmet Ali Nahit Şendur, Cemil Bilir, Bülent Karabulut, İrfan Cicin, Erdem Çubukçu, Mustafa Karaca, Melike Ozcelik, Mehmet Artaç, Eda Tanrikulu, Ahmet Alacacioglu, Özgür Açıkgöz, Başak Öven, Çağlayan Geredeli, Timucin Çil, Hakan Harputluoğlu, Umut Kefeli, Oktay Bozkurt
Backgrounds and ObjectivesColorectal cancer is one of the leading causes of mortality both globally and in our country. In Turkey, we conducted a multicenter investigation into the effectiveness of second-line treatments and real-life data for patients with RAS wild-type metastatic colorectal cancer (NCT04757311).Materials and MethodsIn this retrospective analysis, records from 28 centers were collected
-
Factors affecting medication adherence in patients using oral chemotherapy: A descriptive study J. Oncol. Pharm. Pract. (IF 1.3) Pub Date : 2024-04-13 Eda Unal, Fatma Ilknur Cinar, Canan Porucu
IntroductionThe utilization of oral chemotherapy agents for cancer treatment has witnessed a steady rise in recent years. The pivotal determinant for the success of oral chemotherapy lies in the adherence of cancer patients to the prescribed treatment. This study aims to explore oral chemotherapy adherence and identify factors influencing medication adherence among cancer patients.MethodsA total of
-
Drug-related problems in cancer patients: A systematic review J. Oncol. Pharm. Pract. (IF 1.3) Pub Date : 2024-04-10 Jayalakshmi Venugopal, Shalini S, Rajasekaran A, Deepika Karnan
BackgroundCancer patients are at a significantly increased risk of drug-related problems due to multiple drugs. An inclusive review of drug-related problems would offer an approach for healthcare providers to decrease the frequency of drug-related problems in cancer patients. The purpose of this study was to assess all characteristic components of drug-related problems in cancer patients, and explore
-
Cimetidine repurposed as a potential immunomodulatory agent against colorectal carcinoma: A systematic review J. Oncol. Pharm. Pract. (IF 1.3) Pub Date : 2024-04-09 WWM Gunasekara, JLAA Sachindra, MT Madhushika, PLGC Liyanage, S Lekamwasam
ObjectiveTo determine the survival benefit and immunomodulatory effects of cimetidine pre-, peri- or post-operatively in patients with colorectal cancer (CRC).MethodsA systematic review was conducted using PubMed and Cochrane Library to retrieve randomized control trials (RCTs) that investigated the effects of cimetidine on survival and immunomodulation via improvement in tumor infiltrating lymphocytes
-
Prognostic and predictive biomarkers with therapeutic targets in nonsmall-cell lung cancer: A 2023 update on current development, evidence, and recommendation J. Oncol. Pharm. Pract. (IF 1.3) Pub Date : 2024-04-05 Clement Chung, Godsfavour Umoru
BackgroundSince the publication of the original work in 2014, significant progress has been made in the characterization of genomic alterations that drive oncogenic addiction of nonsmall cell lung cancer (NSCLC) and how the immune system can leverage non-oncogenic pathways to modulate therapeutic outcomes. This update evaluates and validates the recent and emerging data for prognostic and predictive
-
The relationship between immune-related adverse events during ipilimumab monotherapy and survival outcomes among melanoma patients: A systematic review J. Oncol. Pharm. Pract. (IF 1.3) Pub Date : 2024-04-05 Jason Sheng, Manav Nayeni, Monali Malvankar
BackgroundIpilimumab disinhibits immune system activity which results in the elimination of malignant cells. An unintended consequence of ipilimumab therapy is off-target immune-related adverse events (irAEs). It has therefore been proposed that the incidence of irAEs is a manifestation of treatment effectiveness. The objective of this systematic review is to examine the relationship between irAEs
-
Acute pancreatitis associated with pembrolizumab-induced hypertriglyceridemia J. Oncol. Pharm. Pract. (IF 1.3) Pub Date : 2024-04-05 Faisal Inayat, Arslan Afzal, Muhammad Sajeel Anwar, Aamir Saeed, Ahtshamullah Chaudhry, Marjan Haider, Laraib Zulfiqar, Muhammad Sohaib Afzal, Hafiz Muhammad Arslan, Muhammad Wasif Saif
IntroductionAcute pancreatitis (AP) following drug-induced hypertriglyceridemia is a rare clinical phenomenon. Immune checkpoint inhibitors have revolutionized treatment for a variety of solid organ and hematological malignancies. Pembrolizumab is a programmed cell death receptor-1 (PD-1) inhibitor that has shown promising responses in many advanced cancers. However, a constellation of immune-related
-
Administration of teclistamab in four patients with multiple myeloma requiring hemodialysis J. Oncol. Pharm. Pract. (IF 1.3) Pub Date : 2024-04-05 Christy J Khouderchah, Madeleine Ochs, Matthew Pianko, Zahra Mahmoudjafari, Jordan Snyder, Iman Ahmed, Erica Campagnaro, Victoria R Nachar
ObjectiveRelapsed/refractory multiple myeloma (MM) has poor outcomes, especially in heavily pretreated patients. Limited data exists on the use of novel therapies in MM patients with renal dysfunction. This case series describes the successful initiation of teclistamab in four patients with heavily pre-treated MM on hemodialysis (HD).Data SourcesThe medical records of four adult MM patients on HD who
-
A successful desensitization in an adult patient with ARA-C infusion reaction J. Oncol. Pharm. Pract. (IF 1.3) Pub Date : 2024-03-28 Yasemin Akgul Balaban, Mustafa Ilker Inan, Ali Selcuk, Ozgur Kartal, Haydar Zengin, Tuba Bulduk
IntroductionCytarabine (ARA-C) is an antimetabolite agent used especially in the treatment of hematologic malignancies. Infusion reactions have an important place among the side effects that may occur due to treatment. Clinical findings of infusion reactions resemble allergic reactions.Case Report47-year-old male patient with a diagnosis of B-cell Acute Lymphoblastic Leukaemia developed infusion reaction
-
Pembrolizumab induced type 1 diabetes mellitus in a patient with metastatic melanoma and literature review on steroids as a treatment option J. Oncol. Pharm. Pract. (IF 1.3) Pub Date : 2024-03-28 Adina Greene, Scott Penner, Jacqueline Kunesh, Amal Altaf, William McGrade, Jiaxin Niu
ObjectiveWe report a case of a 77-year-old male with metastatic melanoma who developed immune-checkpoint-inhibitor (ICI) induced type 1 diabetes mellitus (T1DM) after seven months of pembrolizumab treatment and required life-long insulin use. This prompted a literature review of best practice guidelines for long-term management of checkpoint-inhibitor induced T1DM including oral steroids as a treatment
-
A real-world multicentre evaluation of atezolizumab plus platinum-etoposide chemotherapy as first-line treatment in patients with extensive-stage small cell lung cancer in Italy J. Oncol. Pharm. Pract. (IF 1.3) Pub Date : 2024-03-27 Felice Musicco, Chiara Fulgenzio, Antonia La Malfa, Nicoletta Jannitti, Antonietta Vitiello, Silvia Carpano, Francesca Fusco, Federico Cappuzzo, Irene Terrenato, Isabella Sperduti, Piera Polidori, Domenico Tarantino, Lidia Di Cerbo, Marcello Pani, Valentina Isgrò, Ruggero Lasala
IntroductionThe aim of this study was to analyze real-life data from a cohort of adult patients receiving atezolizumab in combination with carboplatin and etoposide for first-line treatment of ES-SCLC, in order to assess relative dose intensity (RDI), time-to-treatment discontinuation (TTD), time-to-treatment failure (TTF), progression-free survival (PFS), overall survival (OS) of treatments as well
-
Managing suspected myasthenia gravis and myositis induced by pembrolizumab in a Jehovah's Witness sarcoma patient J. Oncol. Pharm. Pract. (IF 1.3) Pub Date : 2024-03-25 Alexander Hutchinson, Danielle Eskens, Abigail Chan, Anika Bhargava, Ryan Bycroft
IntroductionImmune checkpoint inhibitors (ICIs) can cause a spectrum of adverse events known as immune-related adverse events (irAEs) that resemble autoimmune responses. Immune-mediated myasthenia gravis (MG) is a rare and serious neurologic adverse event that has been associated with ICIs requiring prompt treatment. In the Jehovah's Witness population, typical management of these adverse events may
-
Identifying metrics and designing measurable outcomes in the electronic health record to evaluate pharmacist intervention in an oral chemotherapy program J. Oncol. Pharm. Pract. (IF 1.3) Pub Date : 2024-03-25 Shelby Koppinger, Elizabeth Weil, Nichole Ruffcorn, Erin McGurty, Kevin Creal, Melissa Rhoades
IntroductionDue to the increased utilization of oral anticancer agents, pharmacist-led oral anticancer programs have emerged to meet the needs of oral anticancer management. Currently, at Froedtert & MCW, there is a lack of established tools to collect metrics which demonstrate the value of a pharmacist-led oral anticancer program.MethodsThe purpose of this project is to establish metrics that reflect
-
Clinical activity, pharmacokinetics, and pharmacodynamics of oral hypomethylating agents for myelodysplastic syndromes/neoplasms and acute myeloid leukemia: A multidisciplinary review J. Oncol. Pharm. Pract. (IF 1.3) Pub Date : 2024-03-21 Ryan Haumschild, Julie Kennerly-Shah, Lisa Barbarotta, Amer M. Zeidan
ObjectiveTo review the pharmacokinetic (PK)–pharmacodynamic (PD) profiles, disease setting, dosing, and safety of oral and parenteral hypomethylating agents (HMAs) for the treatment of myelodysplastic syndromes/neoplasms (MDS) and acute myeloid leukemia (AML), and to provide a multidisciplinary perspective on treatment selection and educational needs relating to HMA use.Data SourcesClinical and real-world
-
Innovation in hospital pharmacy: Modeling the installation of automated dispensing systems based on an oncology hospital experience transfer J. Oncol. Pharm. Pract. (IF 1.3) Pub Date : 2024-03-21 Soumaya El Baraka, Ali Cherif Chefchaouni, Aya Bourdaime, Oumaima Lahlou, Yassir El Alaoui, Younes Rahali
ObjectiveThis study explores automated dispensing systems (ADS) implementation in hospitals, focusing on experience transfer between the National Institute of Oncology of Rabat (NIO) and the specialties hospital of Rabat (SHR) to develop a transferable ADS installation and management model.MethodA retrospective implementation and experience data analysis of 3 years ADS implementation at NIO and a prospective
-
Dosing of 7 + 3 induction chemotherapy in a patient with acute myeloid leukemia (AML) and morbid obesity J. Oncol. Pharm. Pract. (IF 1.3) Pub Date : 2024-03-21 Stephanie Franco, Talha Khan, Shira Dinner, Reem Karmali, Megan Melody
IntroductionTraditional chemotherapy dosing is based on body surface area (BSA) using standard formulas, which can pose challenges in dosing patients at body weight extremes. Studies suggest that chemotherapy dosing according to actual body weight does not increase toxicity in obese patients and current guidelines recommend full weight-based dosing of chemotherapy regardless of body mass index (BMI)
-
Hypersensitivity reaction to Abiraterone, successful desensitization protocol in prostate cancer patient J. Oncol. Pharm. Pract. (IF 1.3) Pub Date : 2024-03-15 Sandra N. González Díaz, Oscar Vidal Gutiérrez, José Carlos Rodríguez Román, Raquel A. López Henríquez, Carlos Macouzet Sánchez, Cindy E. de Lira Quezada, Natalhie Acuña Ortega
IntroductionIn prostate cancer, androgens are key in the growth of both normal prostate and cancer cells. Abiraterone acetate inhibits CYP17, an important target in prostate cancer given its central role in the production of adrenal and tumor-derived androgens. Although abiraterone is generally well tolerated, common adverse effects such as hypertension, hypokalemia, and hepatotoxicity have been reported
-
Medical cannabis use in oncology and associated outcomes: A scoping review J. Oncol. Pharm. Pract. (IF 1.3) Pub Date : 2024-03-13 Ana Carolina Valente, Luis Phillipe Nagem Lopes, Maria Eline Matheus
BackgroundNatural and synthetic cannabinoids are being used worldwide to treat various symptoms in cancer patients. This study aims to map the therapeutic benefits and adverse effects associated with the use of cannabis-based drugs in these outcomes.MethodsFollowing Joanna Briggs Institute guidelines a scoping review was conducted. The study protocol was available in the Open Science Framework public
-
Antineoplastic agents associated with neutropenic enterocolitis in patients with malignancy: A quantitative safety signal analysis J. Oncol. Pharm. Pract. (IF 1.3) Pub Date : 2024-03-13 Ali Amanati, Robbert Van Manen, Sarvin Sajedianfard, Hafez Shojaadini, Mohadese Boroughani, Hossein Molavi Vardanjani
BackgroundThe use of certain chemotherapy agents is associated with the development of a condition called “chemotherapy-associated neutropenic enterocolitis” (CANE).ObjectiveTo determine the risk of CANE associated with the use of each antineoplastic agent.MethodsThe FDA FAERS database of spontaneous adverse reactions was searched for the occurrence of the MedDRA preferred term “neutropenic colitis
-
Carboplatin desensitization – simplified 4-step 2-bag method J. Oncol. Pharm. Pract. (IF 1.3) Pub Date : 2024-03-12 Polly E Kintzel, Gregory M Gressel, Brett T Van Rossum, Kristin N Hillaker, Lauren L Ice, Jacqueline J Eastman
IntroductionOur cancer program adopted a method for carboplatin desensitization (4-step 2-bag method) that administers the same intensity of drug exposure with a simplified approach to product management in comparison to a published protocol (4-step 4-bag method).MethodsThe intensity of carboplatin administration for 1:1,000, 1:100, 1:10, and 1:1 dilutions and concomitant fluid administration were
-
Enfortumab-vedotin use for urothelial carcinoma in two patients on hemodialysis J. Oncol. Pharm. Pract. (IF 1.3) Pub Date : 2024-03-12 Harshit Khosla, Sita Bhatt, Ming-Jin Wang, Gretchen Gignac, Kriti Mittal, Jasmine Patel
Enfortumab vedotin (EV) is a novel treatment option for patients with advanced/metastatic urothelial carcinoma who have progressed after chemotherapy and immunotherapy. Two patients at two different New England tertiary cancer care centers were treated with EV while concurrently receiving hemodialysis (HD), where a complete response to EV in both patients was noted. The use of EV in patients requiring
-
Oral anticancer medicine interventions: A cross-sectional study in French community pharmacies J. Oncol. Pharm. Pract. (IF 1.3) Pub Date : 2024-03-08 Florent Macé, Christine Peyron, Amélie Cransac, Pauline Pistre, Mathieu Boulin
IntroductionThe increasing number of oral anticancer medicines (OAMs) dispensed in community pharmacies and the associated challenges (misuse, management of side effects) give the community pharmacist (CP) a major role in the pharmacotherapeutic management of cancer patients. In France, as a response to these challenges, cancer outpatients can schedule a meeting with their CP to ensure the safe and
-
Pharmacist's role in the management of drug–drug interactions caused by nirmatrelvir/ritonavir in COVID-19 oncohematology patients J. Oncol. Pharm. Pract. (IF 1.3) Pub Date : 2024-03-08 Carlos Guzmán Cordero, María Sáez-Torres de Vicente, Álvaro Jiménez Espinosa, Ana Isabel Gago Sánchez
ObjectiveNew drugs developed for SARS-CoV-2 infection, such as nirmatrelvir/ritonavir (NMV/r), represent a potential for oncohematology patients, but also pose a challenge in managing the potential clinically relevant drug–drug interactions (pDDIs) that may arise. The aim of this study is to assess the frequency, severity, and pharmacist detection of pDDIs.MethodsThis prospective, observational, study
-
Selinexor for the treatment of patients with relapsed or refractory multiple myeloma J. Oncol. Pharm. Pract. (IF 1.3) Pub Date : 2024-03-08 Anum Babar, Maham Babar, Hina Zubair, Arzu Shahid, Sana Rafique, Maimona Bano, Madeeha Subhan Waleed, Maimoona Khan, Arslan Inayat, Danish Safi
ObjectiveMultiple myeloma cells resist standard therapies due to overexpression of the transport protein, exportin 1. Selinexor is a novel drug that targets the Exportin 1 protein in these cells.Data sourceA comprehensive search was done, and data showing the efficacy and safety of selinexor in relapsed/refractory multiple myeloma was collected using PubMed, Google Scholar, and clincialtrials.gov.Data
-
Analysis of pharmaceutical interventions in chemotherapy prescriptions of adult and pediatric patients at an oncology reference institute J. Oncol. Pharm. Pract. (IF 1.3) Pub Date : 2024-03-06 Rebeca Gripp de Sá Venancio, Erika da Silva Magliano, Elizangela Domiciano Garcia Barreto
Chemotherapy, one of the primary cancer treatments, has a high risk of causing significant harm in cases of its misuse. Pharmaceutical intervention is one of the strategies used to prevent medication errors from reaching the patient by identifying drug-related problems or other discrepancies related to patient data or medical progress. The primary objective of this study was to analyze the profile
-
Using simulation to improve pharmacy operators’ handling of cytotoxic spills J. Oncol. Pharm. Pract. (IF 1.3) Pub Date : 2024-03-06 Alexandra Garnier, Pascal Bonnabry, Lucie Bouchoud
IntroductionInternational Society of Oncology Pharmacy Practitioners guidelines recommend having standard operating procedures (SOPs) and initial and yearly retraining programs on cytotoxic spill handling for pharmacy operators (POs). This study aimed to create a simulation-based training (SBT) program on this subject and evaluate its impact on POs’ real-life performance.MethodsRandomly formed pairs
-
Palonosetron in pediatric patients: A single-center, retrospective evaluation of policy and clinical practice guideline discordance J. Oncol. Pharm. Pract. (IF 1.3) Pub Date : 2024-03-01 Meredith Ames, Priya Patel, L Lee Dupuis, Alicia Koo
IntroductionClinical practice guidelines (CPGs) recommending palonosetron for the prevention and management of chemotherapy-induced nausea and vomiting (CINV) were adapted for use at our institution. Palonosetron was restricted for use in patients experiencing breakthrough CINV and receiving highly emetogenic chemotherapy (HEC) or undergoing stem cell transplant conditioning and in patients with refractory
-
Comparative study of dexamethasone premedication regimens with docetaxel chemotherapy in early HER-2 positive breast cancer: A safety net hospital experience J. Oncol. Pharm. Pract. (IF 1.3) Pub Date : 2024-03-01 Avery Hager, Shreya Kondle, Amulya Agarwal, Monica Chintapenta, Rochelle Horadam, Navid Sadeghi, Samira Syed
IntroductionDocetaxel can cause fluid retention reactions (FRRs) and hypersensitivity reactions (HSRs). The manufacturer recommends a multi-day oral dexamethasone premedication to prevent these toxicities, but steroid related side effects and regimen compliance remain a concern. This study aimed to determine if modified dexamethasone premedication regimens resulted in differences in HSRs or FRRs to
-
Adhesive capsaicin 8% patch for improved control of pain caused by chemotherapy-induced peripheral neuropathy in patients with multiple myeloma: A single-centre, seven-case series J. Oncol. Pharm. Pract. (IF 1.3) Pub Date : 2024-02-28 Deborah Moreno-Alonso, Sílvia Llorens-Torromé, Blanca Corcoy de Febrer, María Amandi García, Gala Serrano-Bermúdez, Jordi Trelis-Navarro, Victor Mayoral-Rojals, Ancor Serrano-Afonso
BackgroundCapsaicin is a highly selective agonist of the transient receptor potential vanilloid 1. The adhesive capsaicin patch provides a high capsaicin concentration (8%) directly in the painful area – its efficacy in benign peripheral neuropathic pain (diabetic neuropathy or postherpetic neuralgia) has recently been described in the literature. However, there is scant evidence of its efficacy in
-
Successful switch to cisplatin-based chemotherapy in a patient with lung cancer who developed a carboplatin-induced hypersensitivity reaction J. Oncol. Pharm. Pract. (IF 1.3) Pub Date : 2024-02-26 Yuko Nagata, Gouji Toyokawa, Akiko Sugiyama, Shinichiro Shimamatsu, Ohki Saitoh, Hiroshi Okubo, Hitoshi Ueda
IntroductionPlatinum-based chemotherapy is the mainstay of first-line therapy for advanced-stage non-small cell lung cancer (NSCLC). Although carboplatin-induced hypersensitivity reactions (HSRs) commonly occur following multiple cycles of therapy, they are rarely observed during the first cycle of the treatment.Case reportHere, we report the case of a 70-year-old man with advanced-stage NSCLC who
-
Study to evaluate awareness about medication errors and impact of an educational intervention among healthcare personnel in a cancer hospital J. Oncol. Pharm. Pract. (IF 1.3) Pub Date : 2024-02-26 Puskar Kunwor, Bijaya Basyal, Nabin Pathak, Pankaj Vaidya, Sudip Shrestha
IntroductionMedication errors (MEs) are preventable incidents that can result in harm to patients. Therefore, it is essential for healthcare professionals (HCPs) to be well-informed about MEs. This study aims to assess the awareness levels of HCPs and the impact of educational intervention on their understanding of MEs.MethodsResponses to a 17-question structured, self-administered questionnaire assessing
-
Assessment of potential drug–drug interactions in hospitalized cancer patients J. Oncol. Pharm. Pract. (IF 1.3) Pub Date : 2024-02-26 Chameli Ratan, Mekha Rajeev, Karthik Krishnan, Hridya Jayamohanan, Niveditha Kartha, Meenu Vijayan, Keechilat Pavithran
IntroductionDrug–drug interactions (DDIs) pose a significant threat to patients with cancer, resulting in several adverse events in an oncology setting. Our study aims to identify potential DDIs in inpatient oncology wards, assess their severity, and provide recommendations to avoid these interactions.Materials and methodsThis prospective study was conducted in 79 hospitalized cancer patients over
-
Cyclin-dependent kinase 4/6 inhibitors in the treatment of advanced or metastatic breast cancer J. Oncol. Pharm. Pract. (IF 1.3) Pub Date : 2024-02-26 John P Micha, Mark A Rettenmaier, Randy D Bohart, Bram H Goldstein
ObjectiveDespite the relatively high cure rates in early-stage breast cancer, advanced and metastatic breast cancer cases are associated with more inauspicious patient outcomes. Fortunately, with the advent of cyclin-dependent kinase (CDK)4/6 inhibitors (e.g. palbociclib, ribociclib, and abemaciclib) with endocrine therapy, survival in advanced and metastatic breast cancer has appreciably improved
-
Revitalizing oncology medications access in Saudi Arabia: Current challenges and recommendations by the Saudi Oncology Pharmacy Assembly J. Oncol. Pharm. Pract. (IF 1.3) Pub Date : 2024-02-20 Nora Alkhudair, Jude Howaidi, Mohammed Alnuhait, Majed Alshamrani, Mansour Khan, Atika Alharbi, Fouad Alnajjar, Eshtyag Bajnaid, Hajer Almodaheem, Mansour Alhowimel, Ali Alzahrani, Amr Khardaly, Mohammed Alnahedh, Hamdi Elsoudi, Hana Alabdulkareem, Ahmed Alrashidan, Musa Alzahrani, Abdullah Alrajhi
BackgroundCancer care is posing immense challenges to healthcare systems globally. Advances in screening, monitoring, and treating cancer improved patient outcomes and survival rates yet amplified the disease burden. Multiple barriers might impede early access to innovative therapies. We thoroughly examined the current challenges in oncology medication access in Saudi Arabia and provided consensus
-
Evaluation of second-generation Bruton's tyrosine kinase inhibitors for the treatment of mantle cell lymphoma J. Oncol. Pharm. Pract. (IF 1.3) Pub Date : 2024-02-15 Jessie Lu, Bryan Do, Brian Primeaux
IntroductionSecond-generation Bruton's tyrosine kinase (BTK) inhibitors, acalabrutinib and zanubrutinib, are preferred agents for the treatment of relapsed and/or refractory mantle cell lymphoma (MCL) over first-generation BTK inhibitor, ibrutinib. The comparative safety and efficacy of these two agents have not been studied. Currently, the decision between using one second-generation BTK inhibitor
-
Evaluation of cost and infusion-related reactions among intravenous trastuzumab, subcutaneous trastuzumab, and trastuzumab biosimilars at an academic medical center J. Oncol. Pharm. Pract. (IF 1.3) Pub Date : 2024-02-13 Daijah M Davis, Kasey Jackson, Christina Hoppe
IntroductionTrastuzumab is a vital treatment option for human epidermal growth factor 2 positive breast cancer. Since 2017, there have been 5 trastuzumab biosimilars approved for use. Despite hypotheses of infusion-related reactions among intravenous trastuzumab, subcutaneous trastuzumab, and trastuzumab biosimilars, there is minimal available literature comparing these agents. This evaluation will
-
Rechallenges without desensitization following platinum-based chemotherapy reactions J. Oncol. Pharm. Pract. (IF 1.3) Pub Date : 2024-02-13 Fernanda D Young, Sidney Aung, Monica Tang, Karen M Anstey, Michael C Lee, Emely Alfaro, Pelin Cinar, Hansen Ho, Iris M Otani
BackgroundThere is increasing interest in non-desensitization protocols as a potential way to reintroduce chemotherapy following hypersensitivity reactions (HSR).ObjectiveTo provide insight into the potential utility of non-desensitization reintroduction, particularly at institutions where allergy consultation may not be available.MethodsFor 70 patients with platinum HSR who underwent rechallenge with
-
Manual versus automated chemotherapy preparation: A retrospective pharmaco-economic analysis J. Oncol. Pharm. Pract. (IF 1.3) Pub Date : 2024-02-09 Meryem Chennaq, Soumaya El Baraka, Ali Cherif Chefchaouni, Houda Benahmed, Aicha Chaibi, Mohammed-Jaouad Belahcen, Younes Rahali
IntroductionThe National Oncology Institute of Morocco's (NIO) shift to an automated cytotoxic drug preparation system (PHARMODUCT®) has prompted an evaluation of its economic and clinical impacts compared to traditional manual methods.MethodsA retrospective cost-benefit analysis over six months, extrapolated to annual projections, assessed initial investments, labour, equipment, drugs and consumables
-
Pediatric oncology services in Nepal: A special focus on pharmacy practice J. Oncol. Pharm. Pract. (IF 1.3) Pub Date : 2024-02-07 Shreya Dhungana, Nabin Pathak, Bijaya Basyal, Aman Kumar Sah, Anjali Pandit, Puskar Kunwor, Renu Karki
The role of clinical pharmacists or oncology pharmacists in pediatric oncology has been established as important in anticancer regimen review, dose calculation, recommendation, chemocounseling, identification of drug-related problems, its resolution, and, prevention and monitoring of adverse drug reactions within high-income countries. With several hospitals providing pediatric oncology services in
-
Real-world treatment outcomes from a retrospective cohort of patients with acute myeloid leukemia from an urban safety net hospital J. Oncol. Pharm. Pract. (IF 1.3) Pub Date : 2024-02-07 Joseph P Marshalek, Raisa Epistola, Sarah Tomassetti
IntroductionWhile continual advancements in acute myeloid leukemia have augmented response rates and survival, outcomes in clinical trials may not correlate with real-world practice as trials may underrepresent individuals with comorbidities, decreased performance status, and older age. Additionally, clinical trials may underrepresent certain ethnicities, and disparities based on ethnicity, socioeconomic
-
Incidence of pulmonary toxicity in bleomycin-containing regimens for testicular cancer with and without the use of growth factor J. Oncol. Pharm. Pract. (IF 1.3) Pub Date : 2024-01-31 Claire McAvoy, Paige Fields, Danielle Otto, Alexander Kreimer, Carleton S Ellis
IntroductionThe concurrent use of bleomycin and granulocyte colony-stimulating factors (G-CSFs) has historically been debated as a risk factor for bleomycin-induced pulmonary toxicity in patients with both testicular cancer and Hodgkin's lymphoma. The purpose of this study is to evaluate the incidence of pulmonary toxicity in patients with testicular cancer who were treated with bleomycin and pegfilgrastim
-
Concordance analysis of two databases to search for potential drug interactions in onco-hematologic patients J. Oncol. Pharm. Pract. (IF 1.3) Pub Date : 2024-01-31 Pryscila Rodrigues Moreira, Leonardo Teodoro de Farias, Amanda Ribeiro Feitosa, Lunara Teles Silva, Tatyana Xavier Almeida Matteucci Ferreira, Mércia Pandolfo Provin, Rita Goreti Amaral, Ana Carolina Figueiredo Modesto
IntroductionPotential drug interactions exert a significant impact on patient safety, especially within intricate onco-hematological treatments, potentially resulting in toxicity or treatment failures. Despite the availability of databases for potential drug interaction investigation, persistent heterogeneity in concordance rates and classifications exists. The additional variability in database agreement
-
Pembrolizumab-induced agranulocytosis J. Oncol. Pharm. Pract. (IF 1.3) Pub Date : 2024-01-31 Víctor Fernández Martínez, Adela García-Avello Fernández-Cueto, Carmen María Valencia Soto, Sara Barbadillo Villanueva, María Ochagavía Sufrategui, María Rioja Carrera, Lucía Andrea Alonso Buznego, Marta Valero Domínguez
IntroductionWith the widespread use of anti-programmed death-1 monoclonal antibodies, such as pembrolizumab, rare side effects appear in clinical practice.Case reportWe report the case of a man diagnosed with non-keratinizing squamous lung carcinoma stage IVB with programmed death-ligand 1 70% who developed agranulocytosis 10 days after a single dose of pembrolizumab as monotherapy.Management and
-
Incidence and severity of hand-foot syndrome in cancer patients receiving infusional 5-fluorouracil or oral capecitabine-containing chemotherapy regimens J. Oncol. Pharm. Pract. (IF 1.3) Pub Date : 2024-01-24 Sulaikha Abdul Kareem, Simi Grace Joseph, Aneena Wilson, Shahnaz Abdul Kareem, Jobin Kunjumon Vilapurathu
BackgroundHand-foot syndrome is a common adverse effect of 5-fluorouracil infusion or oral capecitabine. Several types of research have shown that clinical presentations of hand-foot syndrome vary by ethnicity, so we tried to look at the incidence and severity of hand-foot syndrome in individuals receiving infusional 5-fluorouracil or oral capecitabine at a tertiary care hospital in central Kerala
-
The risk of pocket infection or bloodstream infection following central venous port placement for the patients with Cetuximab therapy J. Oncol. Pharm. Pract. (IF 1.3) Pub Date : 2024-01-23 Shintaro Sueyoshi, Takeharu Ono, Shun-ichi Chitose, Mioko Fukahori, Takashi Kurita, Hirohito Umeno
ObjectiveCetuximab is a molecular targeted drug that targets epithelial growth factor receptors. The skin toxicity of cetuximab arising from epithelial growth factor inhibition is well known. Some patients with cetuximab therapy decided to make central venous port during the long-term intravenous treatments. Therefore, the author hypothesized that cetuximab administration might increase the risk of
-
Successful desensitization in a patient with recurrent anaplastic oligodendroglioma presenting with procarbazine-mediated anaphylaxis J. Oncol. Pharm. Pract. (IF 1.3) Pub Date : 2024-01-23 Hazal Kayikçi, Özge Can Bostan, Gülseren Tuncay, Melek Cihanbeylerden, Çise Tüccar, Ebru Damadoglu, Gül Karakaya, Ali Fuat Kalyoncu
IntroductionProcarbazine is an oral chemotherapeutic agent used in the treatment of brain malignancies and is associated with hypersensitivity reactions. In case of grade 4 reactions, rechallenge should be avoided, and the agent should be replaced, unless the treatment is curative, in which case the application of a desensitization protocol should be considered. We present a successful case of desensitization
-
Hyperammonemic encephalopathy after tyrosine kinase inhibitors: A literature review and a case example J. Oncol. Pharm. Pract. (IF 1.3) Pub Date : 2024-01-23 Héctor Carlos García-Díaz, Simeon Eremiev, Javier Gómez-Alonso, Joel Veas Rodriguez, Anna Farriols, Maria J Carreras, César Serrano
ObjectiveTo review the evidence of uncommon but fatal adverse event of hyperammonemic encephalopathy by tyrosine kinase inhibitors (TKI) and the possible mechanisms underlying this condition and to describe the case of a patient that developed drug-induced hyperammonemic encephalopathy related to TKI.Data SourcesLiterature search of different databases was performed for studies published from 1 January
-
Chemotherapeutic metabolism presenting as a recalcitrant case of hand–foot syndrome and mucositis J. Oncol. Pharm. Pract. (IF 1.3) Pub Date : 2024-01-11 Kevin R Kwan, Shayna Skokan, Tara Blesh-Boren, Jenilee Vogel, Nicole Harter, James B Ford
IntroductionMercaptopurine (6MP) and methotrexate (MTX) are commonly used for maintenance chemotherapy for acute lymphoblastic leukemia (ALL). These medications have been associated with various side effects such as myelosuppression, colitis, and thyroiditis in addition to numerous cutaneous adverse events. Cutaneous side-effects most reported include mucositis, alopecia, xerosis, and pruritus. We
-
Innovative strategies for effective paclitaxel delivery: Recent developments and prospects J. Oncol. Pharm. Pract. (IF 1.3) Pub Date : 2024-01-11 Sławomir Wileński, Agnieszka Koper, Paulina Śledzińska, Marek Bebyn, Krzysztof Koper
PurposePaclitaxel is an effective chemotherapeutic agent against a variety of cancer types. However, the clinical utility of paclitaxel is restricted by its poor solubility in water and high toxicity, resulting in low drug tolerance. These difficulties could be resolved by using suitable pharmacological carriers. Hence, it is essential to determine innovative methods of administering this effective
-
Correlation analysis of EGFR gene mutation abundance and the efficacy of targeted therapy with osimertinib in nonsmall cell lung cancer—a case control study J. Oncol. Pharm. Pract. (IF 1.3) Pub Date : 2024-01-10 Haiqiang Yan, Jigui Peng, Wang Zhou, Hui Chen, Changjin He
BackgroundIn nonsmall cell lung cancer (NSCLC), epidermal growth factor receptor (EGFR) mutation is the primary cancer-causing mutation. But whether the practical effectiveness of EGFR tyrosine kinase inhibitors (TKIs) can be influenced by plasma EGFR mutation abundance when treating patients with advanced NSCLC remains unanswered. Therefore, this research was intended to reveal the connection between
-
Clinical significance of coadministration of moderate to strong CYP enzyme inhibitors with doxorubicin in breast cancer patients receiving AC chemotherapy J. Oncol. Pharm. Pract. (IF 1.3) Pub Date : 2024-01-10 Amy Priest Dawson, Chrissy D Frick, Megan Burd, Brette Conliffe
IntroductionCytochrome P450 (CYP) enzyme inhibitors may increase the toxicity of many chemotherapies. Medication databases classify doxorubicin coadministration with CYP2D6 or CYP3A4 inhibitors as either a major interaction or contraindication. This study assessed the incidence of toxicity secondary to doxorubicin given with or without CYP enzyme inhibitors in breast cancer patients receiving doxorubicin
-
Incidence of immune-related adverse events in U.S. veterans treated with immune checkpoint inhibitors J. Oncol. Pharm. Pract. (IF 1.3) Pub Date : 2024-01-09 Courtney Krall, Marshall Tague, Brian C Lund
BackgroundImmune checkpoint inhibitors (ICIs) are associated with potentially severe immune-related adverse events (irAEs). Emerging clinical practice reports have suggested higher incidence of irAEs in real-world settings than initially observed in phase III clinical trials. Objectives were to determine the incidence of irAEs associated with ICIs in a clinical population, the Veterans Health Administration
-
Assessing the effectiveness of gabapentin in paclitaxel-induced arthralgia, myalgia, and neuropathic pain: An observational, cohort study J. Oncol. Pharm. Pract. (IF 1.3) Pub Date : 2024-01-05 Prashantkumar Patel, Hemraj Singh Rajput, Khushboo Chavda, Smit Mistry, Sandesh Bhagat, Rajesh Hadia, Moinuddin Saiyed, Avinash Khadela
Background and objectivesArthralgia, myalgia, and neuropathic pain are the most common side effects observed due to paclitaxel chemotherapy. The aim of this study was to investigate the prophylactic role, maintenance, remission, and re-occurrence of arthralgia, myalgia, and neuropathic pain post-gabapentin therapy.MethodologyThis study was conducted in the Department of Oncology, Dhiraj Hospital, Vadodara